Public health & disease

Psilocybin effectively treats depression in cancer patients, new study finds

December 18, 2023 | By Peter Schulte | -, Change Milestones

New research from Maryland-based Sunstone Therapies found that psilocybin-assisted therapy for cancer patients induced a clinically meaningful improvement in depression symptoms, with 80% of participants demonstrating a sustained response and 50% showing full remission of depression symptoms at week one, which was sustained for eight weeks.

Psilocybin effectively treats depression in cancer patients, new study finds Read more

Self-portrait of a woman with cancer and her children

Triple-negative breast cancer vaccine shows good response in first clinical trial of patients

December 15, 2023 | By Peter Schulte | -, Change Milestones

A drug that targets the deadliest form of breast cancer was administered to 16 women in three separate doses in a trial conducted at the Cleveland Clinic with funding from the Pentagon. The trial found that the drug elicits no side effects and triggered an immune response in 75% of patients.

Triple-negative breast cancer vaccine shows good response in first clinical trial of patients Read more

U.S. sets policy to seize patents of government-funded drugs if price deemed too high

December 7, 2023 | By Peter Schulte | -, Change Milestones

“We’ll make it clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House adviser Lael Brainard said on a press call.

U.S. sets policy to seize patents of government-funded drugs if price deemed too high Read more

Once-a-day pill for stubborn cancer delivers a 62.5% positive response

December 5, 2023 | By Peter Schulte | -, Change Milestones

In the first trial, at the Peter MacCallum Cancer Center in Australia, CRC patients receiving just divarasib had a 35.9% positive response rate, which was considered extremely promising.

Once-a-day pill for stubborn cancer delivers a 62.5% positive response Read more

Psilocybin analog leads to 79% of remission in mid-stage depression trial

November 30, 2023 | By Peter Schulte | -, Change Milestones

After only two doses, nearly eight out of ten participants in a phase 2 trial by Toronto-based pharmaceutical company Cybin experienced remission from major depressive disorder at six weeks. The company has a planned phase 3 study slated to commence by the end of Q1 2024.

Psilocybin analog leads to 79% of remission in mid-stage depression trial Read more

New York surgeons perform world’s first successful eyeball transplant

November 15, 2023 | By Peter Schulte | -, Change Milestones

Besides the eyeball, the patient, 46-year-old Aaron James of Hot Springs, Arkansas, also received a partial face transplant and an infusion of donor stem cells to the optic nerve during the more than 20-hour surgery.

New York surgeons perform world’s first successful eyeball transplant Read more

One-dose drug reduced genetic bad cholesterol by 94% for almost a year

November 13, 2023 | By Peter Schulte | -, Change Milestones

Researchers from the Cleveland Clinic have conducted the first human trials of a new drug, lepodisiran, that has the potential to eliminate a risk factor for cardiovascular disease for which there is currently no treatment.

One-dose drug reduced genetic bad cholesterol by 94% for almost a year Read more

Chinese scientists develop novel gene therapy that allows deaf children to hear for the first time

October 31, 2023 | By Peter Schulte | -, Change Milestones

The scientists from Shanghai’s Fudan University implanted new genetic code into a harmless virus and then injected the viruses into the children’s cochlea. They say the experiment has sparked hearing in four out of five children who received the treatment.

Chinese scientists develop novel gene therapy that allows deaf children to hear for the first time Read more

Bangladesh eliminates visceral leishmaniasis

October 31, 2023 | By Peter Schulte | -, Change Milestones

Bangladesh has become the first country globally to be validated for elimination of visceral leishmaniasis, a life-threatening neglected tropical disease. The country achieved the elimination target of less than one case per 10,000 population at the sub-district level in 2017 and has sustained it to date.

Bangladesh eliminates visceral leishmaniasis Read more

North Korea eliminates rubella

October 31, 2023 | By Peter Schulte | -, Change Milestones

North Korea introduced a mass measles-rubella immunization program in November 2019. Through this mass immunization activity, achieving more than 99.8% coverage in almost 6 million target population, the country has rapidly built substantial population immunity for rubella.

North Korea eliminates rubella Read more

Start typing and press enter to search